Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CARLOS ESCASENA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1770852410
CMS profile
1317069
Location
CORAL GABLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$28,792.55

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $14,784.82 27
Biohaven Pharmaceuticals, Inc. $9,488.14 26
Allergan, Inc. $3,715.92 4
Amgen Inc. $707.74 3
Novartis Pharmaceuticals Corporation $63.26 3
Biogen, Inc. $17.73 1
UPSHER-SMITH LABORATORIES LLC $14.94 1

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CARLOS ESCASENA

NPI 1770852410 · CMS profile ID 1317069

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CORAL GABLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770852410?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CARLOS ESCASENA, NPI 1770852410, CMS profile ID 1317069. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770852410?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CARLOS ESCASENA, NPI 1770852410, CMS profile ID 1317069. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770852410?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CARLOS ESCASENA, NPI 1770852410, CMS profile ID 1317069, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1770852410?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $28,792.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–65 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biohaven Pharmaceuticals, Inc. $11.3403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852486383 CMS
Biohaven Pharmaceuticals, Inc. $2.5703/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852486385 CMS
AbbVie Inc. $16.2203/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794414299 CMS
Biohaven Pharmaceuticals, Inc. $24.7703/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852486381 CMS
AbbVie Inc. $6.2703/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794414295 CMS
AbbVie Inc. $11.9202/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794414291 CMS
Biohaven Pharmaceuticals, Inc. $24.2802/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852486379 CMS
Biohaven Pharmaceuticals, Inc. $18.3102/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852486376 CMS
Biohaven Pharmaceuticals, Inc. $9.0502/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852486373 CMS
Biohaven Pharmaceuticals, Inc. $7.7502/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852486371 CMS
Allergan, Inc. $1,920.0001/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792763179 CMS
Allergan, Inc. $23.0901/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792763177 CMS
Biohaven Pharmaceuticals, Inc. $24.0601/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852486369 CMS
Novartis Pharmaceuticals Corporation $20.2301/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812672171 CMS
Allergan, Inc. $1,750.0001/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792763175 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $36,669.56 74
PY2020 $15,880.14 34
PY2021 $28,792.55 65
PY2022 $40,611.82 89
PY2023 $6,806.30 45
PY2024 $6,297.57 58
PY2025 $10,657.69 32

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $809,205.52 56
PY2024 Recipient $180,990.00 1
PY2024 Principal investigator $152,479.58 37
PY2023 Principal investigator $126,799.05 14
PY2022 Principal investigator $708.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

56 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $824.76 12/31/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH LLC
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age No dispute reported 06/30/2026 1202534075
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202534077
Principal investigator 1 ABBVIE INC. $382.00 12/31/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH LLC
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202534079
Principal investigator 1 ABBVIE INC. $750.00 12/24/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202531992
Principal investigator 1 ABBVIE INC. $250.00 12/23/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202531722
Principal investigator 1 ABBVIE INC. $3,418.15 12/04/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202526908
Principal investigator 1 ABBVIE INC. $250.00 11/20/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202524786
Principal investigator 1 ABBVIE INC. $250.00 11/20/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202524788
Principal investigator 1 ABBVIE INC. $5,936.30 11/05/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202521545
Principal investigator 1 ABBVIE INC. $250.00 10/23/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202518245
Principal investigator 1 ABBVIE INC. $250.00 10/23/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202518247
Principal investigator 1 ABBVIE INC. $250.00 09/24/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202512060
Principal investigator 1 ABBVIE INC. $175.50 09/24/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202512062
Principal investigator 1 ABBVIE INC. $250.00 09/24/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202512070
Principal investigator 1 ABBVIE INC. $415.40 09/18/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202511424
Principal investigator 1 ABBVIE INC. $2,675.70 09/03/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202507647
Principal investigator 1 ABBVIE INC. $500.00 08/28/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202506263
Principal investigator 1 ABBVIE INC. $500.00 08/14/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202504579
Principal investigator 1 ABBVIE INC. $15,000.00 08/06/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202502392
Principal investigator 1 ABBVIE INC. $15,000.00 08/06/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202502394
Principal investigator 1 ABBVIE INC. $395.55 08/05/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202501202
Principal investigator 1 ABBVIE INC. $750.00 07/02/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202496525
Principal investigator 1 ABBVIE INC. $750.00 07/02/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202496527
Principal investigator 1 ABBVIE INC. $395.55 07/02/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202496529
Principal investigator 1 ABBVIE INC. $2,501.55 06/03/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202488693
Principal investigator 1 ABBVIE INC. $50.00 05/29/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202486949
Principal investigator 1 ABBVIE INC. $750.00 05/28/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202486491
Principal investigator 1 ABBVIE INC. $750.00 05/28/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202486493
Principal investigator 1 ABBVIE INC. $125.00 05/22/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202485857
Principal investigator 1 ABBVIE INC. $5,670.00 05/15/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202485065
Principal investigator 1 Eli Lilly and Company $9.79 05/12/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187879925
Principal investigator 1 ABBVIE INC. $2,080.00 05/07/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202483361
Principal investigator 1 ABBVIE INC. $75.00 05/06/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481785
Principal investigator 1 ABBVIE INC. $1,821.15 05/06/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481831
Principal investigator 1 ABBVIE INC. $5,000.00 04/17/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202477609
Principal investigator 1 ABBVIE INC. $50.00 04/17/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202477613
Principal investigator 1 ABBVIE INC. $1,250.00 04/07/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202474729
Principal investigator 1 ABBVIE INC. $1,250.00 04/07/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202474735
Principal investigator 1 ABBVIE INC. $680.40 04/03/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202472440
Principal investigator 1 ABBVIE INC. $250.00 04/01/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202467906
Principal investigator 1 ABBVIE INC. $450.00 04/01/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202467910
Principal investigator 1 ABBVIE INC. $125.00 04/01/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202467938
Principal investigator 1 ABBVIE INC. $250.00 04/01/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202467942
Principal investigator 1 ABBVIE INC. $27.00 03/27/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202466754
Principal investigator 1 ABBVIE INC. $5,287.95 03/06/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202457060
Principal investigator 1 ABBVIE INC. $250.00 02/26/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202453996
Principal investigator 1 ABBVIE INC. $1,000.00 02/26/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202454008
Principal investigator 1 ABBVIE INC. $1,000.00 02/26/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202454012
Principal investigator 1 ABBVIE INC. $250.00 02/26/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202454017
Principal investigator 1 ABBVIE INC. $126.37 02/25/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202453806
Principal investigator 1 ABBVIE INC. $2,895.75 02/05/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202444826
Principal investigator 1 ABBVIE INC. $125.00 01/29/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202441811
Principal investigator 1 ABBVIE INC. $250.00 01/16/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202439294
Principal investigator 1 ABBVIE INC. $250.00 01/16/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202439299
Principal investigator 1 Eli Lilly and Company $720,254.00 01/07/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187880221
Principal investigator 1 ABBVIE INC. $3,292.65 01/02/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH OF WESTON
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202434535